Fibrocell Science to Present at 2nd Annual Regen Med Investor Day and BioCentury Future Leaders in the Biotech Industry Conference
Business Wire - Thu Mar 20, 4:30PM CDT
Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today announced that Gregory Weaver, senior vice president and chief financial officer of Fibrocell Science, will present at the Alliance for Regenerative Medicine's (ARM) 2nd Annual Regen Med Investor Day at 4:00 p.m. EDT on Wednesday, March 26, 2014 at the Metropolitan Club in New York, and the BioCentury Future Leaders in the Biotech Industry conference at 10:30 a.m. EDT on Friday, March 28, 2014 at the Millennium Broadway Hotel & Conference Center in New York. Mr. Weaver will discuss the company's autologous fibroblast technology, its therapeutic candidates in development, and its collaboration with Intrexon Corporation (NYSE: XON) to develop genetically-modified personalized biologics.
Earnings Estimates Moving Higher for Fibrocell Science (FCSC): Time to Buy? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 20, 7:46AM CDT
Fibrocell Science (FCSC)sees solid earnings estimate revision activity, and the stock is showing decent short-term momentum as well, rising nearly 24% in the past month.
Intrexon Deal Update Overshadows Q4 Loss at Fibrocell - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 9:00AM CDT
Fibrocell's deal with Intrexon holds great promise.
Fibrocell Science Reports Fourth Quarter and Full Year 2013 Financial and Operating Results
Business Wire - Mon Mar 17, 7:01AM CDT
Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today reported financial results for the fourth quarter and full year ended Dec. 31, 2013. The company will host a conference call and webcast at 8:30 a.m. EDT, today.
Egalet Appoints Timothy P. Walbert to Board of Directors
GlobeNewswire - Tue Mar 11, 7:14AM CDT
Egalet Corporation (Nasdaq:EGLT) ("Egalet"
Fibrocell Science to Report Fourth Quarter and Full Year 2013 Financial and Operating Results, and Host Conference Call and Webcast on March 17
Business Wire - Mon Mar 10, 3:05PM CDT
Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for skin diseases and conditions with high unmet medical needs, today announced that it will report fourth quarter and full-year 2013 financial results and provide an update on the morning of March 17, 2014. The update will include its collaboration with Intrexon Corporation (NYSE:XON). David Pernock, chairman and chief executive officer of Fibrocell, will host the conference call and webcast at 8:30 a.m. EDT, Mar. 17, 2014.
Fibrocell Science to Present at Barclays Global Healthcare Conference 2014
Business Wire - Wed Mar 05, 3:05PM CST
Fibrocell Science (NYSEMKT:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for skin diseases and conditions with high unmet medical needs, today announced that David Pernock, chairman and chief executive officer of Fibrocell Science, will present at the Barclays Global Healthcare Conference 2014 at 2:30 pm EDT on Wednesday, March 12, 2014, at the Loews Hotel in Miami. Mr. Pernock will discuss the company's autologous fibroblast technology, its therapeutic candidates in development, and its collaboration with Intrexon Corporation (NYSE:XON) to develop genetically-modified personalized biologics.
Global Cell Therapy Market & Pipeline Insight Research Report
M2 - Tue Mar 04, 3:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/5kmmgq/global_cell) has announced the addition of the "Global Cell Therapy Market & Pipeline Insight" report to their offering. Research in cell therapy is transforming the future of medicine. As the life of a human being begins as a cell, these cells undergo a highly complex set of events and finally those few stems become capable of self-renewal and differentiation and develop into the specialized cells in the body. Cell therapy research also offers significant potential for restructuring the method of medical practice. Over the past 3-5 years, a more complex therapeutic modality has been is emerging as cell therapies which have been developed to treat diseases which are not amenable to treatment with more classical pharmaceutical or biopharmaceutical products. This market offers the promise of successfully regenerating damaged tissues and organs in the body by replacing the damaged tissue and/or by stimulating the body's own repair mechanisms to heal previously irreparable tissues. With their rising popularity, these therapies are becoming more cost effective and efficient. The global market for cell therapy was valued at close to USD 2.5 Billion in 2012. With continuous advances and developments in this field of medicine, the global cell therapy market is expected to grow at a high rate of 20-22% to reach approximately USD 8 Billion by 2018. Several products and technologies of cell-based therapies are in the R&D pipeline are expected to enter the market during the forecast period, thus resulting in an increased growth rate. It is most likely that the new improved technologies would revolutionize the area of bio-pharma and personalized medicine. Development of sophisticated automation devices for cell expansion and culture process for use in the treatment is one of the emerging trends of ACT market. With the cell-based therapies growing by leaps and bounds, it is expected that the future years would witness significant advancements in technology in the cell therapy market. Increasing incidence of diseases along with lack of adequate effective treatment for these diseases is most likely to drive the cell therapy technology in developed and developing nations. Among the emerging trends of the global market, the most prominent one is the development of sophisticated automation devices for cell expansion and culture process which could be used in the treatment of life threatening diseases. Global Cell Therapy Market & Pipeline Insight Report Highlights & Findings: - Introduction to Cell therapy - Global Cell Therapy Market Overview - Global Cell Therapy Market Dynamics - Cell Therapy Pipeline by Phase, Country & Target Indications - Cell Therapy Drugs in Pipeline: More Than 200 - Highest Number of Drugs in Preclinical Stage: 73 - Number of Drugs in Phase I/II Stage: 35 - Key Market: US - Majority Cell therapies For Cancer Treatment Companies Mentioned - Advanced Cell Technology - Amgen - California Stem Cell - Celgene Corporation - Cytomedix - Fibrocell Science - Genzyme - NeoStem - Novartis - Stemedica Cell Technologies For more information visit http://www.researchandmarkets.com/research/5k...lobal_cell About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Western Union Announces $0.125 Quarterly Dividend
Business Wire - Fri Feb 21, 1:51PM CST
The Western Union Company (NYSE: WU) announced today that its board of directors declared a quarterly cash dividend of $0.125 per common share, payable March 31, 2014 to stockholders of record at the close of business on March 17, 2014.
Norsat 2013 Year-End Earnings Release and Conference Call Notice
Business Wire - Wed Feb 19, 7:00AM CST
Norsat International Inc. ("Norsat" or "the Company"
5 Stocks With Big Insider Buying
at The Street - Wed Jan 29, 12:22PM CST
Insiders at these companies have been scooping up shares of their own stock lately.
Intrexon: Living Better Through Synthetic Biology?
at Investor's Business Daily - Tue Jan 28, 1:03PM CST
Analysts have dropped their profit estimates for synthetic biotechnology firm Intrexon, and investors seem to be taking it in stride. Intrexon (XON) stock has soared this year, mainly on investor hopes of better results to come later from royalties...
Fibrocell Science and Intrexon Expand Collaboration to Include Hypermobility-Type Ehlers-Danlos Syndrome
PR Newswire - Mon Jan 13, 7:30AM CST
Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for skin diseases and conditions with high unmet medical needs, and Intrexon Corporation (NYSE: XON), a leader in synthetic biology, announced today an expansion of their Exclusive Channel Collaboration (ECC) to develop a treatment for Ehlers-Danlos syndrome hypermobility type (EDS-HT), a rare genetic disorder resulting in weakened connective tissue.
Global Burns Clinical Trials Report - H2 2013 Edition
M2 - Fri Jan 10, 8:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/4vpq56/burns_global) has announced the addition of the "Burns Global Clinical Trials Review, H2, 2013" report to their offering. This report provides elemental information and data relating to the clinical trials on Burns. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Burns. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Burns Therapeutics Clinical Trials - MediWound Ltd. - Fibrocell Science, Inc. - Bayer AG - Plethora Solutions Holdings plc - Kuros Biosurgery AG - Klinikum St. Georg gGmbH - HealOr Ltd. - Fresenius SE & Co. KGaA - Birken AG - Baxter International Inc. Clinical Trial Overview of Top Institutes / Government - The University of Texas Medical Branch at Galveston - Massachusetts General Hospital - Shriners Hospitals for Children - U.S. Army Institute of Surgical Research - Shiraz University of Medical Sciences - National Institute of General Medical Sciences - Tehran University of Medical Sciences - Association of Dutch Burn Centres - Third Military Medical University - Johns Hopkins University For more information visit http://www.researchandmarkets.com/research/4v...rns_global
Fibrocell Science Appoints Robert Sheroff, Vice President of Technical Operations
Business Wire - Mon Jan 06, 6:59AM CST
Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for skin diseases and conditions with high unmet medical needs, today announced that Robert Sheroff has been appointed vice president of technical operations for the company. In this newly-created position, Mr. Sheroff will be responsible for managing the growing manufacturing needs of azficel-T, as well as manufacturing genetically-modified fibroblast based products.
Fibrocell Science's chairman and CEO David Pernock joins Alliance for Regenerative Medicine's board
M2 - Tue Dec 17, 11:58AM CST
Cell therapy company Fibrocell Science Inc (NYSE MKT:FCSC) reported on Monday the addition of its chairman and CEO David Pernock to Alliance for Regenerative Medicine's (ARM) board.
Fibrocell Science Chairman & CEO David Pernock Joins Board of Alliance for Regenerative Medicine
Business Wire - Mon Dec 16, 7:00AM CST
Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for skin diseases and conditions with high unmet medical needs, today announced Chairman and CEO David Pernock has joined the board of the Alliance for Regenerative Medicine (ARM), a global advocacy organization whose diverse membership represents leading regenerative medicine companies and investors, university-based and non-profit research institutions, patient advocacy groups, pharmaceutical companies engaged in regenerative medicine research, and other organizations supporting regenerative medicine.
2013 Report on the International Collagen and HA-Based Biomaterials Market
M2 - Mon Dec 02, 4:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/dbnhsw/collagen_and#summary) has announced the addition of the "2013 Report on the International Collagen and HA-Based Biomaterials Market" report to their offering. Biomaterials are of vital importance in the medical device industry, both for the discovery and development of synthetic organs, aesthetic procedures, and personal healthcare products. Growth in the biomaterials market continues to be fueled by heightened interest in personal healthcare and growing size of aging population. The dynamic and diverse market for biomaterials, comprising collagen and hyaluronic acid-based (HA-based) products, is led by the US market, as stated by the new market research report on Collagen and HA-based Biomaterials market. The US is followed by Europe and Japan. Key growth drivers of the collagen and hyaluronic acid-based products include increasing prevalence of diseases, including osteoarthritis, along with a greater importance on fitness and health in old age. Other drivers include development of new products with wide application areas; introduction of single-injection visco supplement products for osteoarthritis patients; strong growth in the under-penetrated developing markets, including the Asia-Pacific region; new vistas in implantable devices, tissue engineering, bone grafting substance, and facial aesthetic dermal fillers. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Global Market Overview 2. Market Trends And Issues 3. Biomaterials - A Brief Overview 4. Segment Overview 5. Product Introductions/Innovations 6. Recent Industry Activity 7. Corporate Activity In The Recent Past - A Perspective Builder 8. Focus On Select Key Players 9. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Rest Of World IV. Competitive Landscape Total Companies Profiled: 63 (including Divisions/Subsidiaries - 69) - The United States (44) - Canada (2) - Japan (3) - Europe (18) - France (1) - Germany (3) - The United Kingdom (5) - Italy (1) - Rest of Europe (
Fibrocell Science Announces Third Quarter 2013 Financial Results
Business Wire - Thu Nov 14, 7:45AM CST
Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for skin diseases and conditions, particularly those with high unmet medical needs, today announced financial results for the third quarter ended September 30, 2013 and provided an update on recent business developments.
Fibrocell Science Honored with Partner in Progress Award from DEBRA of America
Business Wire - Fri Oct 25, 7:30AM CDT
Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company primarily focused on developing innovative products for skin diseases and conditions, today announced the company was honored with a Partners in Progress Award from the Dystrophic Epidermolysis Bullosa Research Association of America (DEBRA). The award recognizes the company's recent work developing potential therapies for those with epidermolysis bullosa (EB), a rare, genetic, connective tissue disorder for which there is no treatment or cure. David Pernock, Chairman and CEO of Fibrocell Science, accepted the award during the 15th Annual DEBRA of America Benefit at The Museum of Modern Art in New York City on October 24, 2013.